Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal